The article "thrombocytopenia among patients undergoing aortic valve replacement using the sutureless perceval s bioprosthesis" was reviewed.The article presented a restrospective single center study, to compare the incidence, severity, and clinical implications of thrombocytopenia after aortic valve replacement (avr) using the perceval s or the trifecta bioprosthesis.Abbott devices used included the trifecta aortic valve.The article concluded that the perceval s bioprosthesis was associated with more severe postoperative thrombocytopenia.[the primary author and corresponding author was matthias kirschwith corresponding email matthias.Kirsch@chuv.Ch.The time frame of the study was march 2016 to august 2019.A total of 156 patients were included in this study, of which 53 received an abbott device.Comorbidities include previous myocardial infarction, congestive heart failure, diabetes, hypertension, hypercholesterolemia, chronic obstructive pulmonary disease, cerebrovascular arteriopathy, lower extremity arterial disease, previous valve replacement, aortic regurgitation, and bicuspid aortic valve.
|